“Current Scientific Concepts and Practices in DMPK: Drug Transporters, DDI, Formulation Strategies, and Clinical Pharmacology”
Somerset Crowne Plaza Hotel
110 Davidson Avenue
Somerset, New Jersey
April 13, 2011
8:00 am – 3:45 pm
Program
08:00 am
Registration / Continental Breakfast / Vendor Exhibit
09:00 am
Introductory Remarks [slides (PDF)]
Dr. Imad Hanna, Chair, NJDMDG
09:10 am
Structure and Function of Human “Multidrug And Toxin Extruders” (MATEs) [slides (PDF)]
Dr. Stephen Wright, Professor of Physiology, Biochemistry and Molecular Biophysics, Department of Physiology, University of Arizona, Tucson, AZ.
10:00 am
Factors Influencing Drug Delivery to the Brain: Multiple Mechanisms at Multiple Barriers [slides (PDF)]
Dr. William F. Elmquist, Professor and Department Head Department of Pharmaceutics, University of Minnesota, Minneapolis MN.
10:45 am
Vendor Exhibit & Coffee Break
11:30 am
Irreversible Inhibition of CYP2C19 by Some but not all Proton Pump Inhibitors and its Relevance to the Anti-Platelet Effect of Clopidogrel (Plavix) [slides (PDF)]
Dr. Andrew Parkinson, Chief Scientific Officer, XenoTech LLC, Lenexa, KS.
12:15 pm
Lunch & Vendor Exhibit
01:45 pm
Formulation-Dependent PK/PD and Human Dose Projections Using In silico, In vitro and In vivo Data
Dr. Tycho Heimbach, Senior Investigator, Drug Metabolism and Pharmacokinetics, Novartis Institute for BioMedical Research, East Hanover, NJ
02:30 pm
Vendor Exhibit & Coffee Break
03:00 pm
Developing the Clinical Pharmacology Section of a U.S. Package Insert [slides (PDF)]
Dr. Philip Mayer, Assistant Vice President of Clinical Pharmacology, Pfizer Global Research and Development, Collegeville, PA.
03:45 pm
Program Closure
The latest issue of The Indicator is now available for download.
